TARS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Tarsus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $275.21 Mil. Tarsus Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was $349.28 Mil. Therefore, Tarsus Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.79.
The historical rank and industry rank for Tarsus Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
During the past 6 years, the highest Equity to Asset Ratio of Tarsus Pharmaceuticals was 0.97. The lowest was -0.57. And the median was 0.83.
The historical data trend for Tarsus Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | -0.10 | 0.97 | 0.93 | 0.85 | 0.74 |
Tarsus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.82 | 0.78 | 0.80 | 0.74 | 0.79 |
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Tarsus Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 196.988 | / | 265.491 | |
= | 0.74 |
Tarsus Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Equity to Asset (Q: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 275.211 | / | 349.278 | |
= | 0.79 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (NAS:TARS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Bobak R. Azamian | director, 10 percent owner, officer: President and CEO | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Jose M. Trevejo | officer: Chief Medical Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Andrew D. Goldberg | director | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Dianne C. Whitfield | officer: Chief Human Resources Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bryan Wahl | officer: General Counsel | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Jeffrey S Farrow | officer: See Remarks | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Leonard M. Greenstein | officer: Chief Financial Officer | 24562 BELGREEN PLACE, LAKE FOREST CA 92630 |
Seshadri Neervannan | officer: Chief Operating Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Mark J. Holdbrook | officer: V.P., Clinical Affairs | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Michael Ackermann | director, 10 percent owner | 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
Rosemary A Crane | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
From GuruFocus
By PurpleRose PurpleRose • 08-05-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Marketwired • 11-01-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023
By GuruFocusNews GuruFocusNews • 06-25-2022
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 08-24-2023
By GlobeNewswire • 08-02-2023
By GuruFocus Research • 12-02-2023
By Value_Insider Value_Insider • 12-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.